Exelixis | EXEL - Capitale Sociale E Riserve





Capitale Sociale E Riserve Cambiamento Data
Acadia Pharmaceuticals USD 1.25B 20.68M 2026-03
Agios Pharmaceuticals USD 1.11B 84M 2026-03
Akebia Therapeutics USD 27.38M 5.24M 2026-03
Amgen USD 9.19B 532M 2026-03
AstraZeneca USD 47.33B 1.33B 2026-03
Bayer EUR 28.85B 2.9B 2026-03
BioMarin Pharmaceutical USD 6.21B 125.11M 2026-03
Bristol-Myers Squibb USD 20.07B 1.6B 2026-03
Cytokinetics USD -826.57M 166.94M 2026-03
Eisai JPY 898.99B 9.36B 2026-03
Eli Lilly USD 31.2B 4.66B 2026-03
Esperion Therapeutics USD -307.93M 5.97M 2026-03
Exelixis USD 1.94B 225.57M 2026-03
Genmab DKK 5.85B 96M 2025-12
Glaxosmithkline GBP 22.06B 360M 2025-12
Incyte USD 5.62B 455.37M 2026-03
Ionis Pharmaceuticals USD 491.41M 2.32M 2026-03
MacroGenics USD 21.2M 34.39M 2026-03
Merck USD 45.88B 6.73B 2026-03
Moderna USD 7.41B 1.24B 2026-03
Nektar Therapeutics USD 89.83M 4.75M 2025-12
Neurocrine Biosciences USD 3.41B 154.3M 2026-03
Novartis USD 38.93B 7.2B 2026-03
Pfizer USD 90.1B 3.63B 2026-03
Puma Biotechnology USD 115.27M 10.55M 2025-09
Sanofi EUR 71.71B 14.25B 2025-12
Takeda JPY 7.77T 129.5B 2026-03
Ultragenyx Pharmaceutical USD -236M 156M 2026-03
Xencor USD 515.63M 119.95M 2026-03